Rona Z. Silkiss

Northwestern University Medical School

Graves' disease, Cosmetic Botox, Bags under eyes, Basal cell carcinoma, Entropion, Ectropion

Plastic / Cosmetic Surgeon, Physician

Spanish

Neuroanatomic Variations in Graves' Dysthyroid Ophthalmopathy as Studied With MRI. Silkiss RZ, Wade AR. Trans Am Ophthalmol Soc. 2016 Aug;114:T9. Epub 2017 May 24., Inflammatory Mediators in Xanthelasma Palpebrarum: Histopathologic and Immunohistochemical Study. Govorkova MS, Milman T, Ying GS, Pan W, Silkiss RZ. Ophthalmic Plast Reconstr Surg. 2018 May/Jun;34(3):225-23, Clinical Response to Tocilizumab in Severe Thyroid Eye Disease. Sy A, Eliasieh K, Silkiss RZ. Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3):e55-e57, , , Predicting the Development of Orbitopathy in Graves Thyroidopathy Patients: The Potential Role of TSI Testing. Takakura A, Kirkeby K, Earle K, Silkiss RZ. Ophthalmic Plast Reconstr Surg. 2015 Sep-Oct;31(5):369-7, Indications and limitations of vismodegib for basal cell carcinoma--reply. Gill HS, Moscato EE, Silkiss RZ. JAMA Ophthalmol. 2014 Jul;132(7):906. doi: 10.1001/jamaophthalmol.2014.1805, Vismodegib for periocular and orbital basal cell carcinoma. Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ. JAMA Ophthalmol. 2013 Dec;131(12):1591-4, Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease. Gess AJ, Silkiss RZ. Ophthalmic Plast Reconstr Surg. 2014 Jan-Feb;30(1):e11-3, New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, Oro AE, Chang AL. JAMA Dermatol. 2013 Feb;149(2):242-3, Rituximab for thyroid eye disease. Silkiss RZ, Reier A, Coleman M, Lauer SA. Ophthalmic Plast Reconstr Surg. 2010 Sep-Oct;26(5):310-4., Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy. Nielsen JF, El Fassi D, Nielsen CH, Hegedüs L, Lauer SA, Silkiss RZ, Prause JU. Acta Ophthalmol. 2009 Nov;87(8):927-9, Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus. Silkiss RZ, Lee H, Gills Ray VL. Arch Ophthalmol. 2009 Mar;127(3):345-6, Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. J Clin Endocrinol Metab. 2007 Oct;92(10):3762-3., Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Ho VH, Chevez-Barrios P, Jorgensen JL, Silkiss RZ, Esmaeli B. Tissue Antigens. 2007 Aug;70(2):105-9. Erratum in: Tissue Antigens. 2008 Feb;71(2):185. Silkis, R , Autogenous fat grafting by injection. Silkiss RZ, Baylis HI. Ophthalmic Plast Reconstr Surg. 1987;3(2):71-5., Revascularization studies of an opposing eyelid pedicle flap. Silkiss RZ, Glasgow BJ, Baylis HI. Ophthalmic Plast Reconstr Surg. 1989;5(2):110-7., Transcanalicular THC:YAG dacryocystorhinostomy. Silkiss RZ, Axelrod RN, Iwach AG, Vassiliadis A, Hennings DR. Ophthalmic Surg. 1992 May;23(5):351-3., THC:YAG nasolacrimal duct recanalization. Silkiss RZ. Ophthalmic Surg. 1993 Nov;24(11):772-4., Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients. McCracken MS, Khan JA, Wulc AE, Holds JB, Fante RG, Migliori ME, Ebroon DA, Lenalidomide-Associated Thyroid-Related Eyelid Retraction. Slean GR, Silkiss RZ. Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):e46-e48., Gene Expression Profiling and Heterogeneity of Nonspecific Orbital Inflammation Affecting the Lacrimal Gland. Rosenbaum JT, Choi D, Harrington CA, Wilson DJ, Grossniklaus HE, Sibley CH, Salek SS, Ng JD, Dailey RA, Steele EA, Hayek B, Craven CM, Edward DP